Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

Atopic dermatitis is a chronic, non-infectious inflammatory dermatosis. Acharacteristic
feature is persistent itching of the skin. The chronic, relapsing course of the disease …

Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …

Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

The exponential growth of precision diagnostic tools, including omic technologies, molecular
diagnostics, sophisticated genetic and epigenetic editing, imaging and nano‐technologies …

There has been extensive progress in understanding the cellular and molecular
mechanisms of inflammation and immune regulation in allergic diseases of the skin and …

Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic
challenge with increasingly recognized different phenotypes among variable patient …

Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …

abstract Atopic dermatitis (AD) is a heterogenous disorder and can be classified into
different types. Stratification of subtypes may enable personalized medicine approaches. AD …

Importance Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of
atopic dermatitis (AD) pathophysiology. Objective To evaluate the efficacy and safety of …